Advertisement

Clinical Policy: Use of Intravenous Tissue Plasminogen Activator for the Management of Acute Ischemic Stroke in the Emergency Department

      Policy statements and clinical policies are the official policies of the American College of Emergency Physicians and, as such, are not subject to the same peer review process as articles appearing in the journal. Policy statements and clinical policies of ACEP do not necessarily reflect the policies and beliefs of Annals of Emergency Medicine and its editors.
      To read this article in full you will need to make a payment
      ACEP Member Login
      ACEP Members, full access to the journal is a member benefit. Use your society credentials to access all journal content and features.
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Edlow J.A.
        • Smith E.E.
        • Stead L.G.
        • et al.
        • American College of Emergency Physicians and American Academy of Neurology
        Clinical policy: use of intravenous tPA for the management of acute ischemic stroke in the emergency department.
        Ann Emerg Med. 2013; 61: 225-243
        • Go A.S.
        • Mozaffarian D.
        • Roger V.L.
        • et al.
        • American Heart Association Statistics Committee and Stroke Statistics Subcommittee
        Heart disease and stroke statistics — 2014 update: a report from the American Heart Association.
        Circulation. 2014; 129: e28-e292
        • Kochanek K.D.
        • Xu J.
        • Murphy S.L.
        • et al.
        Deaths: final data for 2009.
        Natl Vital Stat Rep. 2011; 60: 1-116
        • Newman D.H.
        • Schuur J.D.
        Streetlights and quality measures for stroke.
        Ann Emerg Med. 2014; 64: 245-247
        • Jauch E.C.
        • Saver J.L.
        • Adams Jr., H.P.
        • et al.
        • American Heart Association Stroke Council, Council on Cardiovascular Nursing, Council on Peripheral Vascular Disease, and Council on Clinical Cardiology
        Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association.
        Stroke. 2013; 44: 870-947
        • Lansberg M.G.
        • O’Donnell M.J.
        • Khatri P.
        • et al.
        Antithrombotic and thrombolytic therapy for ischemic stroke: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
        Chest. 2012; 141: e601S-e636S
        • Banks J.L.
        • Marotta C.A.
        Outcomes validity and reliability of the modified Rankin Scale: implications for stroke clinical trials: a literature review and synthesis.
        Stroke. 2007; 38: 1091-1096
      1. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke.
        N Engl J Med. 1995; 333: 1581-1587
        • Gumbinger C.
        • Gruschka P.
        • Bottinger M.
        • et al.
        Improved prediction of poor outcome after thrombolysis using conservative definitions of symptomatic hemorrhage.
        Stroke. 2012; 43: 240-242
        • Hoffman J.R.
        • Schriger D.L.
        A graphic reanalysis of the NINDS trial.
        Ann Emerg Med. 2009; 54: 329-336
      2. PRISMS trial. ClinicalTrials.gov: NCT02072226. Available at: https://clinicaltrials.gov/ct2/show/NCT02072226. Accessed November 7, 2014.

        • Christakis D.A.
        • Zimmerman F.J.
        Rethinking reanalysis.
        JAMA. 2013; 310: 2499-2500
        • Feng W.
        • Vasquez G.
        • Suri F.K.
        • et al.
        Repeated-measures analysis of the National Institute of Neurological Disorders and Stroke rt-PA stroke trial.
        J Stroke Cerebrovasc Dis. 2011; 20: 241-246
        • Marler J.R.
        • Tilley B.C.
        • Lu M.
        • et al.
        Early stroke treatment associated with better outcome. The NINDS rt-PA stroke study.
        Neurology. 2000; 55: 1649-1655
        • Saver J.L.
        • Gornbein J.
        • Starkman S.
        Graphic reanalysis of the two NINDS-tPA trials confirms substantial treatment benefit.
        Stroke. 2010; 41: 2381-2390
        • Johnston K.C.
        • Connors Jr., A.F.
        • Wagner D.P.
        • et al.
        Risk adjustment effect on stroke clinical trials.
        Stroke. 2004; 35: e43-e45
        • Saver J.L.
        • Yafeh B.
        Confirmation of tPA treatment effect by baseline severity-adjusted end point reanalysis of the NINDS-tPA stroke trials.
        Stroke. 2007; 38: 414-416
        • Kwiatkowski T.
        • Libman R.
        • Tilley B.C.
        • et al.
        The impact of imbalances in baseline stroke severity on outcome in the National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study.
        Ann Emerg Med. 2005; 45: 377-384
        • Ingall T.J.
        • O’Fallon W.M.
        • Asplund K.
        • et al.
        Findings from the reanalysis of the NINDS tissue plasminogen activator for acute ischemic stroke treatment trial.
        Stroke. 2004; 35: 2418-2424
        • Mazighi M.
        • Chaudhry S.A.
        • Ribo M.
        • et al.
        Impact of onset-to-reperfusion time on stroke mortality: a collaborative pooled analysis.
        Circulation. 2013; 127: 1980-1985
        • Hacke W.
        • Kaste M.
        • Bluhmki E.
        • et al.
        • ECASS Investigators
        Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke.
        N Engl J Med. 2008; 359: 1317-1329
        • Hacke W.
        • Kaste M.
        • Fieschi C.
        • et al.
        Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II).
        Lancet. 1998; 352: 1245-1251
        • Sandercock P.
        • Wardlaw J.M.
        • Lindley R.I.
        • et al.
        • for the IST-3 Collaborative Group
        The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third International Stroke Trial [IST-3]): a randomised controlled trial.
        Lancet. 2012; 379: 2352-2363
        • Wardlaw J.M.
        • Murray V.
        • Berge E.
        • et al.
        Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis.
        Lancet. 2012; 379: 2364-2372
        • Emberson J.
        • Lees K.R.
        • Lyden P.
        • et al.
        • for the Stroke Thrombolysis Trialists’ Collaborative Group
        Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials.
        Lancet. 2014; 384: 1929-1935
        • Aoki J.
        • Kimura K.
        • Koga M.
        • et al.
        NIHSS-time score easily predicts outcomes in rt-PA patients: The SAMURAI rt-PA registry.
        J Neurol Sci. 2013; 327: 6-11
        • Hirano T.
        • Sasaki M.
        • Tomura N.
        • et al.
        • Japan Alteplase Clinical Trial Group
        Low Alberta stroke program early computed tomography score within 3 hours of onset predicts subsequent symptomatic intracranial hemorrhage in patients treated with 0.6 mg/kg alteplase.
        J Stroke Cerebrovasc Dis. 2012; 21: 898-902
        • Karlinski M.
        • Kobayashi A.
        • Mikulik R.
        • et al.
        Intravenous alteplase in ischemic stroke patients not fully adhering to the current drug license in Central and Eastern Europe.
        Int J Stroke. 2012; 7: 615-622
        • Lang W.
        • Stadler C.H.
        • Poljakovic Z.
        • et al.
        A prospective, randomized, placebo-controlled, double-blind trial about safety and efficacy of combined treatment with alteplase (rt-PA) and Cerebrolysin in acute ischaemic hemispheric stroke.
        Int J Stroke. 2013; 8: 95-104
        • Abilleira S.
        • Davalos A.
        • Chamorro A.
        • et al.
        Outcomes of intravenous thrombolysis after dissemination of the stroke code and designation of new referral hospitals in Catalonia: the Catalan Stroke Code and Thrombolysis (Cat-SCT) monitored study.
        Stroke. 2011; 42: 2001-2006
        • Antoncic I.
        • Dunatov S.
        • Bralic M.
        • et al.
        Intravenous thrombolysis for acute ischemic stroke — our experiences.
        Coll Antropol. 2011; 35: 483-486
        • Bhatnagar P.
        • Sinha D.
        • Parker R.A.
        • et al.
        Intravenous thrombolysis in acute ischaemic stroke: a systematic review and meta-analysis to aid decision making in patients over 80 years of age.
        J Neurol Neurosurg Psychiatry. 2011; 82: 712-717
        • Liao X.L.
        • Wang C.X.
        • Wang Y.L.
        • et al.
        • Thrombolysis Implementation and Monitor of acute ischemic Stroke in China (TIMS-China) Investigators
        Implementation and outcome of thrombolysis with alteplase 3 to 4.5 h after acute stroke in Chinese patients.
        CNS Neurosci Ther. 2013; 19: 43-47
        • Martins S.C.
        • Friedrich M.A.
        • Brondani R.
        • et al.
        Thrombolytic therapy for acute stroke in the elderly: an emergent condition in developing countries.
        J Stroke Cerebrovasc Dis. 2011; 20: 459-464
        • Sung P.S.
        • Chen C.H.
        • Hsieh H.C.
        • et al.
        Outcome of acute ischemic stroke in very elderly patients: is intravenous thrombolysis beneficial?.
        Eur Neurol. 2011; 66: 110-116
        • Park T.H.
        • Lee J.S.
        • Park S.S.
        • et al.
        Safety and efficacy of intravenous recombinant tissue plasminogen activator administered in the 3- to 4.5-hour window in Korea.
        J Stroke Cerebrovasc Dis. 2014; 23: 1805-1812
        • Ahmed N.
        • Kellert L.
        • Lees K.R.
        • et al.
        Results of intravenous thrombolysis within 4.5 to 6 hours and updated results within 3 to 4.5 hours of onset of acute ischemic stroke recorded in the Safe Implementation of Treatment in Stroke International Stroke Thrombolysis Register (SITS-ISTR). An observational study.
        JAMA Neurol. 2013; 70: 837-844
        • Sung S.F.
        • Chen S.C.
        • Lin H.J.
        • et al.
        Comparison of risk-scoring systems in predicting symptomatic intracerebral hemorrhage after intravenous thrombolysis.
        Stroke. 2013; 44: 1561-1566
        • Alias M.
        • Staff I.
        • McCullough L.D.
        Early experience with community implementation of thrombolysis three to 4.5 hours after acute ischemic stroke.
        Conn Med. 2011; 75: 531-536
        • Chao T.H.
        • Lin T.C.
        • Shieh Y.
        • et al.
        Intracerebral hemorrhage after thrombolytic therapy in acute ischemic stroke patients with renal dysfunction.
        Eur Neurol. 2013; 70: 316-321
        • Cronin C.A.
        • Sheth K.N.
        • Zhao X.
        • et al.
        Adherence to third European Cooperative Acute Stroke Study 3- to 4.5-hour exclusions and association with outcome: data from Get With the Guidelines — Stroke.
        Stroke. 2014; 45: 2745-2749
        • Flint A.C.
        • Gupta R.
        • Smith W.S.
        • et al.
        • SITS International and VISTA-plus investigators
        The THRIVE score predicts symptomatic intracerebral hemorrhage after intravenous tPA administration in SITS-MOST.
        Int J Stroke. 2014; 9: 705-710
        • Mehrpour M.
        • Aghaei M.
        • Motamed M.R.
        Safety and feasibility of intravenous thrombolytic therapy in Iranian patients with acute ischemic stroke.
        Med J Islam Repub Iran. 2013; 27: 113-118
        • Saver J.L.
        • Fonarow G.C.
        • Smith E.E.
        • et al.
        Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke.
        JAMA. 2013; 309: 2480-2488
        • Chowdhury M.
        • Birns J.
        • Rudd A.
        • et al.
        Telemedicine versus face-to-face evaluation in the delivery of thrombolysis for acute ischaemic stroke: a single centre experience.
        Postgrad Med J. 2012; 88: 134-137
        • Saarinen J.T.
        • Sillanpaa N.
        • Rusanen H.
        • et al.
        The mid-M1 segment of the middle cerebral artery is a cutoff clot location for good outcome in intravenous thrombolysis.
        Eur J Neurol. 2012; 19: 1121-1127
        • Kono S.
        • Deguchi K.
        • Morimoto N.
        • et al.
        Tissue plasminogen activator thrombolytic therapy for acute ischemic stroke in 4 hospital groups in Japan.
        J Stroke Cerebrovasc Dis. 2013; 22: 190-196
        • Seet R.C.
        • Zhang Y.
        • Wijdicks E.F.
        • et al.
        Thrombolysis outcomes among obese and overweight stroke patients: an age- and National Institutes of Health Stroke Scale–matched comparison.
        J Stroke Cerebrovasc Dis. 2014; 23: 1-6
        • McKinney J.S.
        • Masjuan J.
        • Purroy F.
        • et al.
        Safety of thrombolytic therapy for acute ischemic stroke after recent transient ischemic attack.
        J Stroke Cerebrovasc Dis. 2012; 21: 551-554
        • Wardlaw J.M.
        • Murray V.
        • Berge E.
        • et al.
        Thrombolysis for acute ischaemic stroke (review).
        Cochrane Database Syst Rev. 2014; 7: CD000213
        • Topakian R.
        • Brainin M.
        • Eckhardt R.
        • et al.
        Thrombolytic therapy for acute stroke in Austria: data from the Safe Implementation of Thrombolysis in Stroke (SITS) register.
        Eur J Neurol. 2011; 18: 306-311
        • Clark W.M.
        • Wissman S.
        • Albers G.W.
        • et al.
        • ATLANTIS Study Investigators
        Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The Atlantis Study: a randomized controlled trial.
        JAMA. 1999; 282: 2019-2026
        • Ebinger M.
        • Scheitz J.F.
        • Kufner A.
        • et al.
        MRI-based intravenous thrombolysis in stroke patients with unknown time of symptom onset.
        Eur J Neurol. 2012; 19: 348-350
        • Garcia-Bermejo P.
        • Calleja A.I.
        • Perez-Fernandez S.
        • et al.
        Perfusion computed tomography–guided intravenous thrombolysis for acute ischemic stroke beyond 4.5 hours: a case-control study.
        Cerebrovasc Dis. 2012; 34: 31-37
        • Paliwal P.R.
        • Ahmad A.
        • Shen L.
        • et al.
        Persistence of hyperdense middle cerebral artery sign on follow-up CT scan after intravenous thrombolysis is associated with poor outcome.
        Cerebrovasc Dis. 2012; 33: 446-452
        • Sairanen T.
        • Soinila S.
        • Nikkanen M.
        • et al.
        Two years of Finnish telestroke: thrombolysis at spokes equal to that at the hub.
        Neurology. 2011; 76: 1145-1152
        • Sobolewski P.
        • Sledzinska-Dzwigal M.
        • Szczuchniak W.
        • et al.
        The efficacy and safety of intravenous thrombolysis with alteplase in the treatment of ischaemic stroke in a rural hospital.
        Neurol Neurochir Pol. 2013; 47: 310-318
        • Strbian D.
        • Ringleb P.
        • Michel P.
        • et al.
        Ultra-early intravenous stroke thrombolysis. Do all patients benefit similarly?.
        Stroke. 2013; 44: 2913-2916
        • Turc G.
        • Apoil M.
        • Naggara O.
        • et al.
        Magnetic resonance imaging–DRAGON score: 3-month outcome prediction after intravenous thrombolysis for anterior circulation stroke.
        Stroke. 2013; 44: 1323-1328
        • Vujkovic Z.
        • Racic D.
        • Miljkovic S.
        • et al.
        Hemorrhagic complications of thrombolytic therapy.
        Med Pregl. 2012; 65: 9-12
        • Xian Y.
        • Liang L.
        • Smith E.E.
        • et al.
        Risks of intracranial hemorrhage among patients with acute ischemic stroke receiving warfarin and treated with intravenous tissue plasminogen activator.
        JAMA. 2012; 307: 2600-2608
        • Zinkstok S.M.
        • Roos Y.B.
        • ARTIS Investigators
        Early administration of aspirin in patients treated with alteplase for acute ischaemic stroke: a randomised controlled trial.
        Lancet. 2012; 380: 731-737
        • Dharmasaroja P.A.
        • Dharmasaroja P.
        • Muengtaweepongsa S.
        Outcomes of Thai patients with acute ischemic stroke after intravenous thrombolysis.
        J Neurol Sci. 2011; 300: 74-77
        • Fischer U.
        • Mono M.L.
        • Zwahlen M.
        • et al.
        Impact of thrombolysis on stroke outcome at 12 months in a population: the Bern stroke project.
        Stroke. 2012; 43: 1039-1045
        • Al-Khaled M.
        • Matthis C.
        • Eggers J.
        Predictors of in-hospital mortality and the risk of symptomatic intracerebral hemorrhage after thrombolytic therapy with recombinant tissue plasminogen activator in acute ischemic stroke.
        J Stroke Cerebrovasc Dis. 2014; 23: 7-11
        • Tong X.
        • George M.G.
        • Yang Q.
        • et al.
        Predictors of in-hospital death and symptomatic intracranial hemorrhage in patients with acute ischemic stroke treated with thrombolytic therapy: Paul Coverdell Acute Stroke Registry 2008-2012.
        Int J Stroke. 2014; 9: 728-734
        • Yeo L.L.
        • Paliwal P.
        • Teoh H.L.
        • et al.
        Early and continuous neurologic improvements after intravenous thrombolysis are strong predictors of favorable long-term outcomes in acute ischemic stroke.
        J Stroke Cerebrovasc Dis. 2013; 22: e590-e596
        • Dharmasaroja P.A.
        • Muengtaweepongsa S.
        • Pattaraarchachai J.
        • et al.
        Intracerebral hemorrhage following intravenous thrombolysis in Thai patients with acute ischemic stroke.
        J Clin Neurosci. 2012; 19: 799-803
        • Meurer W.J.
        • Kwok H.
        • Skolarus L.E.
        • et al.
        Does preexisting antiplatelet treatment influence postthrombolysis intracranial hemorrhage in community-treated ischemic stroke patients? An observational study.
        Acad Emerg Med. 2013; 20: 146-154
        • Paciaroni M.
        • Agnelli G.
        • Caso V.
        • et al.
        Intravenous thrombolysis for acute ischemic stroke associated to extracranial internal carotid artery occlusion: the ICARO-2 study.
        Cerebrovasc Dis. 2012; 34: 430-435
        • Messe S.R.
        • Fonarow G.C.
        • Smith E.E.
        • et al.
        Use of tissue-type plasminogen activator before and after publication of the European Cooperative Acute Stroke Study III in Get With the Guidelines—Stroke.
        Circ Cardiovasc Qual Outcomes. 2012; 5: 321-326
        • Wong E.H.
        • Lau A.Y.
        • Soo Y.O.
        • et al.
        Is stroke thrombolysis safe and efficacious in Hong Kong?.
        Hong Kong Med J. 2012; 18: 92-98
        • Ebinger M.
        • Winter B.
        • Wendt M.
        • et al.
        Effect of the use of ambulance-based thrombolysis on time to thrombolysis in acute ischemic stroke. A randomized clinical trial.
        JAMA. 2014; 311: 1622-1631
        • Fonarow G.C.
        • Zhao X.
        • Smith E.E.
        Door-to-needle times for tissue plasminogen activator administration and clinical outcomes in acute ischemic stroke before and after a quality improvement initiative.
        JAMA. 2014; 311: 1632-1640
        • Hsieh C.Y.
        • Lin H.J.
        • Sung S.F.
        • et al.
        Is renal dysfunction associated with adverse stroke outcome after thrombolytic therapy?.
        Cerebrovasc Dis. 2014; 37: 51-56
        • Reiter M.
        • Teuschi Y.
        • Matz K.
        • et al.
        Diabetes and thrombolysis for acute stroke: a clear benefit for diabetics.
        Eur J Neurol. 2014; 21: 5-10
        • Strbian D.
        • Michel P.
        • Seiffge D.J.
        • et al.
        Symptomatic intracranial hemorrhage after stroke thrombolysis: comparison of prediction scores.
        Stroke. 2014; 45: 752-758
        • Ciccone A.
        • Valvassori L.
        • Nichelatti M.
        • et al.
        • SYNTHESIS Expansion Investigators
        Endovascular treatment for acute ischemic stroke.
        N Engl J Med. 2013; 368: 904-913
        • Matijevic V.
        • Poljakovic Z.
        • Malojcic B.
        • et al.
        Systemic thrombolytic therapy in acute ischemic stroke — new experiences in spreading network of stroke units in Croatia.
        J Neurol Sci. 2012; 314: 126-129
        • Lahoti S.
        • Gokhale S.
        • Caplan L.
        • et al.
        Thrombolysis in ischemic stroke without arterial occlusion at presentation.
        Stroke. 2014; 45: 2722-2727
        • Lyerly M.J.
        • Albright K.C.
        • Boehme A.K.
        • et al.
        Safety of protocol violations in acute stroke tPA administration.
        J Stroke Cerebrovasc Dis. 2014; 23: 855-860
        • Murao K.
        • Leys D.
        • Jacquin A.
        • et al.
        • OPHELIE-COG Investigators
        Thrombolytic therapy for stroke in patients with preexisting cognitive impairment.
        Neurology. 2014; 82: 2048-2054
        • Goyal M.
        • Demchuk A.M.
        • Menon B.K.
        • et al.
        • ESCAPE Trial Investigators
        Randomized assessment of rapid endovascular treatment of ischemic stroke.
        N Engl J Med. 2015; 372: 1019-1030
        • Campbell B.C.
        • Mitchell P.J.
        • Kleinig T.J.
        • et al.
        • EXTEND-IA Investigators
        Endovascular therapy for ischemic stroke with perfusion-imaging selection.
        N Engl J Med. 2015; 372: 1009-1018
        • Kent D.M.
        • Rothwell P.M.
        • Ioannidis J.P.
        • et al.
        Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal.
        Trials. 2010; 11: 85
        • Kent D.M.
        • Hayward R.A.
        Limitations of applying summary results of clinical trials to individual patients. The need for risk stratification.
        JAMA. 2007; 298: 1209-1212
        • Kent D.M.
        • Selker H.P.
        • Ruthazer R.
        • et al.
        The stroke-thrombolytic predictive instrument: a predictive instrument for intravenous thrombolysis in acute ischemic stroke.
        Stroke. 2006; 37: 2957-2962
        • Gonzalez R.G.
        • Lev M.H.
        • Goldmacher G.V.
        • et al.
        Improved outcome prediction using CT angiography in addition to standard ischemic stroke assessment: results from the STOPStroke study.
        PLoS One. 2012; 7: e30352
        • Menon B.K.
        • Saver J.L.
        • Prabhakaran S.
        • et al.
        Risk score for intracranial hemorrhage in patients with acute ischemic stroke treated with intravenous tissue-type plasminogen activator.
        Stroke. 2012; 43: 2293-2299
        • Chao A.C.
        • Liu C.K.
        • Chen C.H.
        • et al.
        • Taiwan Thrombolytic Therapy for Acute Ischemic Stroke (TTT-AIS) Study Group
        Different doses of recombinant tissue-type plasminogen activator for acute stroke in Chinese patients.
        Stroke. 2014; 45: 2359-2365
        • Singh B.
        • Parsaik A.K.
        • Prokop L.J.
        • et al.
        Endovascular therapy for acute ischemic stroke: a systematic review and meta-analysis.
        Mayo Clin Proc. 2013; 88: 1056-1065
        • Hill M.D.
        • Demchuk A.M.
        • Goyal M.
        • et al.
        Alberta Stroke Program early computed tomography score to select patients for endovascular treatment. Interventional Management of Stroke (IMS)-III Trial.
        Stroke. 2014; 45: 444-449
        • Berkhemer O.A.
        • Fransen P.S.
        • Beumer D.
        • et al.
        • The MR CLEAN Investigators
        A randomized trial of intraarterial treatment for acute ischemic stroke.
        N Engl J Med. 2015; 372: 11-20
        • Saver J.L.
        • Goyal M.
        • Bonafe A.
        • et al.
        • SWIFT PRIME Investigators
        Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke.
        N Engl J Med. 2015; 372: 2285-2295
        • Flynn D.
        • Knoedler M.A.
        • Hess E.P.
        • et al.
        Engaging patients in health care decisions in the emergency department through shared decision-making: a systematic review.
        Acad Emerg Med. 2012; 19: 959-967
        • Legare F.
        • Witteman H.O.
        Shared decision making: examining key elements and barriers to adoption into routine clinical practice.
        Health Aff (Millwood). 2013; 32: 276-284
        • Hoffmann T.C.
        • Montori V.M.
        • Del Mar C.
        The connection between evidence-based medicine and shared decision making.
        JAMA. 2014; 312: 1295-1296
        • Hoffmann T.C.
        • Del Mar C.
        Patients’ expectations of the benefits and harms of treatments, screening, and tests. A systematic review.
        JAMA Intern Med. 2014;Dec 22; : E1-E13
        • Flynn D.
        • Ford G.A.
        • Stobbart L.
        • et al.
        A review of decision support, risk communication and patient information tools for thrombolytic treatment in acute stroke: lessons for tool developers.
        BMC Health Serv Res. 2013; 13: 1-13
        • Gadhia J.
        • Starkman S.
        • Ovbiagele B.
        • et al.
        Assessment and improvement of figures to visually convey benefit and risk of stroke thrombolysis.
        Stroke. 2010; 41: 300-306

      Linked Article